Company Overview of ViaCyte, Inc.
ViaCyte, Inc., a preclinical stage stem cell engineering company, develops and commercializes cell therapies to treat diabetes in the United States and internationally. The company develops human embryonic stem cells for Type 1 and Type 2 diabetic patients, as well as therapies based on pancreatic beta cell progenitors derived from human pluripotent stem cells. It develops insulin-producing cells from human embryonic stem cells to produce islet cells; and Encaptra, a vascularizing device that enables implanted pancreatic progenitor cells to survive and differentiate into functioning islet cells. The company was formerly known as Novocell, Inc. and changed its name to ViaCyte, Inc. in May 201...
3550 General Atomics Court
San Diego, CA 92121
Founded in 1999
Key Executives for ViaCyte, Inc.
Chief Executive Officer and President
Vice President of Finance and Corporate Controller
Chief Medical Officer and Vice President of Clinical Development
Senior Vice President of Science & Technology
Chief Development Officer and Vice President of Device Research & Development
Compensation as of Fiscal Year 2014.
ViaCyte, Inc. Key Developments
ViaCyte, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:20 AM
Feb 22 15
ViaCyte, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:20 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.
ViaCyte, Inc. Receives Clearance from Health Canada for Diabetes Clinical Trial
Jan 8 15
ViaCyte, Inc. received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the company's Phase 1/2 clinical trial of its VC-01TM product candidate. The VC-01 product candidate is currently being evaluated in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. The location and enrollment start date of the first Canadian clinical trial site have not yet been disclosed. The Investigational New Drug application for the Phase 1/2 trial, called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was allowed by the US Food and Drug Administration in August 2014. The STEP ONE trial was launched in September 2014 at UC San Diego Health System, with the support of the UC San Diego Sanford Stem Cell Clinical Center and under the direction of Principal Investigator Robert Henry, MD. The first implant was performed in October 2014. In addition to determining the safety of the product candidate in these patients, STEP ONE is designed to evaluate the effectiveness of the VC-01 product candidate in replacing the lost endocrine function that is central to the disease. In an open-label, dose-escalating format, ViaCyte expects to enroll approximately 40 patients in the study at multiple clinical sites.
ViaCyte, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 through Jan-15-2015
Nov 24 14
ViaCyte, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 through Jan-15-2015. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Presentation Date & Speakers: Jan-12-2015, Paul K. Laikind, Chief Executive Officer and President. Jan-13-2015, Paul K. Laikind, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 8, 2014